Monograph Details
|
|
Eye Disorders
> Glaucoma
|
|
BETOPTIC S |
| Manufacturer |
|
Alcon Laboratories, Inc. |
| Legal Classification |
|
Rx
|
| Pharmacological Class |
|
Cardioselective β-blocker. |
| Generic Name |
|
Betaxolol HCl 0.25%; oph. susp; contains benzalkonium chloride. |
| Indications |
|
Open-angle glaucoma. Ocular hypertension. |
| Children |
|
Not recommended. |
| Adults |
|
1–2 drops twice daily. |
| Contraindications |
|
Sinus bradycardia. Greater than 1st-degree AV block. Cardiogenic shock. Overt cardiac failure. |
| Precautions |
|
History of cardiac failure or heart block. Discontinue at 1st sign of cardiac failure. COPD. Asthma. Pulmonary impairment. Measure intraocular pressure during 1st month of treatment. Diabetes (esp. labile). May mask hypoglycemia and hyperthyroidism. Discontinue before general anesthesia. Avoid abrupt cessation. Pregnancy (Cat.C). Nursing mothers. |
| Interactions |
|
May potentiate or be potentiated by systemic β-blockers. May potentiate reserpine, hypoglycemics. May antagonize adrenergic psychotropics. |
| Adverse Reactions |
|
Transient discomfort, tearing. Rarely: decreased corneal sensitivity, erythema, itch, corneal punctate staining, keratitis, anisocoria, photophobia, depression, headache, bradycardia, dyspnea, hives. |
| How Supplied |
|
Susp—2.5mL, 5mL, 10mL, 15mL |
|
|
|
|
